PROCYSBI(R) Receives Positive Opinion for Orphan Drug Exclusivity From the EU Committee for Orphan Medicinal Products
22 juil. 2013 07h00 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has received a positive opinion from the European Union (EU) Committee for Orphan...
Raptor's PROCYSBI(TM) Receives U.S. Orphan Drug Exclusivity
25 juin 2013 16h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 25, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the Office of Orphan Product Development at the Food and Drug Administration (FDA)...
Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results
06 mars 2013 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
Aegerion Pharmaceuticals Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID(TM) (lomitapide) Capsules
07 janv. 2013 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
LaVoie Group Issues White Paper: Solving the Unique Problems of Orphan Drug Communications
18 oct. 2012 10h40 HE
|
LaVoie Health Science
Cambridge, MA, Oct. 18, 2012 (GLOBE NEWSWIRE) -- LaVoie Strategic
Communications Group, Inc. (LaVoie Group), the acknowledged
leader in life science, medtech and pharmaceutical communications,
today...
Hemispherx Biopharma Announces Filing a New Drug Application in Argentina for Ampligen(R) to Treat Chronic Fatigue Syndrome
18 juil. 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 18, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it has submitted a new drug application to ANMAT (Administracion...
Aegerion Pharmaceuticals Announces FDA Acceptance of New Drug Application for Review
30 avr. 2012 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations for Therapeutic to Treat Hemoglobin Disorders
26 mars 2009 12h54 HE
|
HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - March 26, 2009) - HemaQuest Pharmaceuticals today announced that
it has received two orphan medicinal product designations from the European
Commission for its product...
HemaQuest Pharmaceuticals Announces Clinical Progress on New Sickle Cell Anemia Drug
09 déc. 2008 12h01 HE
|
HemaQuest Pharmaceuticals
SAN FRANCISCO, CA--(Marketwire - December 9, 2008) - HemaQuest Pharmaceuticals announced
today the successful completion of Phase 1 clinical trials of HQK-1001, an
orally-administered therapeutic...